This was the stock's second consecutive day of losses.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with ...

Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, ...

These funds reward investors with high distributions and target capital appreciation as a secondary objective.

According to Report Ocean, the US Urinary Tract Infection (UTI) Therapeutics market is anticipated to grow at a CAGR of ~$% between 2022-2028 owing to rise in cases of UTIs, technological advancements ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,015.83 today based on a ...

In the most recent trading session, AbbVie (ABBV) closed at $179.53, indicating a -0.32% shift from the previous trading day.

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...